Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis

The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis

(2020) Christian Lunetta et al.   JOURNAL OF NEUROLOGY

Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients

(2020) Yasuyuki Ohta et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Reappraisal of an ALS trial: unaccounted procedural risk

(2020) John Turnbull   LANCET NEUROLOGY

Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System

(2020) Michelle Vu et al.   JAMA Network Open

Early post-marketing experience with edaravone in an unselected group of patients with ALS

(2019) Alon Abraham et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Edaravone for the treatment of amyotrophic lateral sclerosis

(2019) Hiide Yoshino   Expert Review of Neurotherapeutics

Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy

(2019) Andrea Fortuna et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Is edaravone harmful? (A placebo is not a control)

(2018) John Turnbull   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

(2017) Koji Abe et al.   LANCET NEUROLOGY

Amyotrophic Lateral Sclerosis

(2017) Robert H. Brown et al.   NEW ENGLAND JOURNAL OF MEDICINE

Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis

(2017) Fumihiro Takahashi et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis

(2017) Koji Takei et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

July 2017 ENCALS statement on edaravone

(2017) Ammar Al-Chalabi et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Impact of Postapproval Evidence Generation on the Biopharmaceutical Industry

(2015) Christopher-Paul Milne et al.   CLINICAL THERAPEUTICS

Edaravone's free radical scavenging mechanisms of neuroprotection against cerebral ischemia: review of the literature

(2014) Yanxin Ren et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

(2014) Koji Abe et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger

(2011) Masashi Aoki et al.   BRAIN RESEARCH

Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications

(2009) Murtuza Bharmal et al.   Health and Quality of Life Outcomes

Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice

(2008) Hidefumi Ito et al.   EXPERIMENTAL NEUROLOGY